FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
PEG-MGF 2mg research peptide vial
Growth & Longevity

PEG-MGF

PEGylated mechano growth factor

A PEGylated MGF with extended stability for muscle-repair research.

From $120

In stock · ships in 1–2 business days

  • ✓ ≥98.5% purity
  • ✓ HPLC + mass-spec tested
  • ✓ Batch COA available
  • ✓ Discreet US shipping
IGF-1 variantmuscle research

Research Summary

PEG-MGF is a PEGylated form of mechano growth factor with extended half-life, studied in preclinical research for prolonged satellite-cell and muscle-repair signaling. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

PEG-MGF: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is PEG-MGF?

PEG-MGF is mechano growth factor (MGF) with polyethylene glycol (PEG) chains attached. MGF itself is a synthetic peptide matching the C-terminal E domain of an IGF-1 splice variant, IGF-1Ec in humans and IGF-1Eb in rodents [1]. The background, mechanisms, and open questions for the parent peptide are covered on our MGF research page.

We want to be direct about the evidence. As of October 12, 2026, a PubMed search for PEG-MGF returned a single record: a 2026 narrative review that lists PEGylated MGF among IGF-1 analogues marketed as "research compounds," notes the absence of regulatory approval and the uncertainty around product composition in unregulated supply chains, and stratifies such peptides into evidence tiers that run down to a complete absence of human studies [2]. We did not find a peer-reviewed study that tested PEG-MGF itself in cells or animals. Most of what is said about PEG-MGF online is an extrapolation from MGF plus general PEGylation chemistry.

PEG-MGF molecular identity
NamePEGylated mechano growth factor (PEG-MGF)
Base peptideMechano growth factor (MGF), the E-domain peptide of an IGF-1 splice variant
ModificationConjugation to polyethylene glycol (PEG)
PubChemNo PubChem compound record (checked 2026-10-12)
Peer-reviewed studiesNone found that test PEG-MGF itself (PubMed, checked 2026-10-12)

What PEGylation changes

PEGylation is a long-established technique in peptide and protein chemistry. A 2003 review in Nature Reviews Drug Discovery explained that attaching PEG chains increases a molecule's mass and shields it from proteolytic enzymes, which can slow renal clearance and degradation and so lengthen circulating half-life for many peptides and proteins [3]. Whether, and by how much, this applies to the MGF peptide has not been reported in the peer-reviewed literature.

PEG is not biologically invisible. A 2015 review described antibodies that bind PEG itself, which can accelerate clearance of PEGylated molecules. In animals this response was typically robust but short-lived, and the review noted that anti-PEG antibodies have been detected even in healthy untreated people, with many questions about human anti-PEG immunity still open [4]. This is one reason PEGylated research compounds should not be assumed to behave like their parent peptide.

What the evidence covers

  • Parent peptide. Cell and animal studies of the unmodified MGF peptide exist, but a 2014 replication attempt by two pharmaceutical research groups found no effect on myoblast or muscle stem cell proliferation or differentiation [5]. See the MGF page for detail.
  • PEG-MGF itself. No peer-reviewed cell, animal, or human study was found [2].
  • Human data. FDA's compounding safety-risk page states that the agency identified no human exposure data for PEG-MGF by any route [6].

Any laboratory work with PEG-MGF is, in practice, characterization work: confirming identity and conjugation, and comparing it against unmodified MGF and mature IGF-1 as controls.

Regulatory status

  • Not FDA approved. No drug application for PEG-MGF appears in FDA's Drugs@FDA database, as checked on October 12, 2026 [7].
  • Compounding. FDA's list of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) lists Mechano Growth Factor Pegylated (PEG-MGF) among substances whose nominations were withdrawn. FDA noted that compounded drugs containing it may pose a significant risk of immunogenicity, cited complexities in peptide-related impurities and characterization, and stated that it had identified no human exposure data [6]. PEG-MGF was not among the six peptides that FDA's Pharmacy Compounding Advisory Committee recommended for the 503A bulks list in July 2026 [8].
  • Sport. The World Anti-Doping Agency's Prohibited List names mechano growth factors (MGFs) under S2.3, growth factors and growth factor modulators, prohibited at all times [9].

Rejuvatide supplies PEG-MGF strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

A lot-specific certificate of analysis for PEG-MGF is not yet published on this site. You can request the batch COA through our COA library, and we will only describe tests for this product once the laboratory's certificate is posted there. Ordering and shipping questions are answered in our FAQ.

Browse related compounds in growth-axis research, including MGF and IGF-1 LR3.

Storage of lyophilized material

PEG-MGF ships as a lyophilized (freeze-dried) powder. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

PEG-MGF FAQ

What is PEG-MGF?

PEG-MGF is mechano growth factor, a synthetic IGF-1 splice-variant E-domain peptide, conjugated to polyethylene glycol. It is sold for laboratory research only.

Is there published research on PEG-MGF?

Very little. As of October 2026, PubMed held one review that mentions PEG-MGF and no study that tested it directly. Most claims about it are extrapolated from unmodified MGF and general PEGylation chemistry.

How is PEG-MGF different from MGF?

PEGylation adds polyethylene glycol chains, which in general increase molecular size and protect peptides from enzymatic breakdown. Its specific effect on MGF has not been characterized in peer-reviewed work.

Is PEG-MGF FDA approved?

No. It has no FDA drug approval, and FDA lists it among bulk substances that may present significant safety risks in compounding, citing immunogenicity concerns and no human exposure data.

Is PEG-MGF banned in sport?

WADA names mechano growth factors (MGFs) under S2.3 of its Prohibited List, a class prohibited at all times.

Is PEG-MGF for human use?

No. Rejuvatide sells PEG-MGF for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. Kandalla PK, Goldspink G, Butler-Browne G, et al. Mech Ageing Dev. 2011;132(4):154-62. PubMed 21354439
  2. Dominikowski A, Rękoś Z, Olejarz M, et al. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
  3. Harris JM, Chess RB. Nat Rev Drug Discov. 2003;2(3):214-21. PubMed 12612647
  4. Yang Q, Lai SK. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(5):655-77. PubMed 25707913
  5. Fornaro M, Hinken AC, Needle S, et al. Am J Physiol Endocrinol Metab. 2014;306(2):E150-6. PubMed 24253050
  6. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  7. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs database (searched October 12, 2026). Source
  8. National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound (July 31, 2026). Source
  9. World Anti-Doping Agency. The 2026 Prohibited List, S2.3 Growth Factors and Growth Factor Modulators. Source